Holen Sie sich die Stockscreener-App
14.88
1.29%
-0.195
Vorhandelsmarkt:
14.32
-0.56
-3.76%
Schlusskurs vom Vortag:
$15.07
Offen:
$14.9
24-Stunden-Volumen:
1.89M
Relative Volume:
0.57
Marktkapitalisierung:
$47.35B
Einnahmen:
$29.96B
Nettoeinkommen (Verlust:
$957.25M
KGV:
48.95
EPS:
0.304
Netto-Cashflow:
$4.77B
1W Leistung:
-2.11%
1M Leistung:
+2.76%
6M Leistung:
+3.77%
1J Leistung:
+0.40%
1-Tages-Spanne:
$14.81
$14.90
1-Wochen-Bereich:
$14.81
$15.55
52-Wochen-Spanne:
$12.80
$15.55
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Vergleichen Sie TAK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.88 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
ZTS
Zoetis Inc
|
154.79 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
HLN
Haleon Plc Adr
|
9.63 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.15 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
309.22 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - GlobeNewswire Inc.
IBD Rating Upgrades: Ameren Shows Improved Technical Strength - inkl
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
The 30-day ADR trend, in yen terms, shows high values for Keyence, Kyocera Corporation Sponsored ADR, and Murata Manufacturing. - 富途牛牛
Takeda Pharma ADR earnings beat by $150.82, revenue fell short of estimates - Investing.com UK
On the 21st, ADR movements in yen terms showed high values for NISSAN MOTOR CO LTD, NINTENDO CO LTD, and Sumitomo Trust. - 富途牛牛
Why This Biotech's Dive Benefits Its Top Three Rivals - Investor's Business Daily
Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector (TAK) - Seeking Alpha
Behind Takeda Pharmaceutical Co ADR’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug - Investing.com
Takeda stock rises after positive Phase 3 results for narcolepsy drug By Investing.com - Investing.com South Africa
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Purchased by Allspring Global Investments Holdings LLC - Defense World
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
Nomura Holdings Inc ADR (NYSE:NMR) Shares Acquired by GAMMA Investing LLC - Defense World
Hengan International Group (OTCMKTS:HEGIY) Stock Price Up 3.7% – Time to Buy? - Defense World
Expedia Group Earns RS Rating Upgrade - inkl
GAMMAGARD LIQUID ERC, GAMMAGARD LIQUID and GAMMAGARD S/D U.S. Important Safety Information - Placera.se
Stocks With Rising Relative Price Strength: IREN - inkl
Stocks With Rising Relative Strength: Dr. Reddy's Labs ADR - inkl
Nano Dimension Ltd ADR’s Shares Reel: -28.07% Quarterly Revenue Decline Amid 329.06M Market Cap - investchronicle.com
MNST’s Stock Market Adventure: 19.08% YTD Growth Amidst Volatility - investchronicle.com
On the 10th, the ADR trends show that Takeda Pharmaceutical, Nidec Corporation Sponsored ADR, Advantest, and others are performing well in terms of yen conversion. - 富途牛牛
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
EU approves Takeda’s new Hodgkin lymphoma treatment - Investing.com
IgA nephropathy Pipeline Drugs Analysis 2025: Clinical Trials, - openPR.com
CTVA’s Stock Market Adventure: 22.38% YTD Growth Amidst Volatility - investchronicle.com
Takeda files executive compensation report with SEC - Investing.com
Cameco Earns Relative Strength Rating Upgrade; Hits Key Threshold - inkl
TD Cowen maintains Buy on Takeda, reiterates $16 target - Investing.com
Stocks With Rising Relative Strength: Novartis ADR - inkl
Fidelity Natl Info Svcs Shows Rising Relative Strength; Still Shy Of Key Benchmark - inkl
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus - Wiley Online Library
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Financial Metrics Unveiled: Topgolf Callaway Brands Corp (MODG)’s Key Ratios in the Spotlight - DWinneX
Ratios Reveal: Breaking Down Takeda Pharmaceutical Co ADR (TAK)’s Financial Health - DWinneX
Balance Sheet Insights: Nuveen Churchill Direct Lending Corp (NCDL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Takeda continues stock plan for management in 2025 - Investing.com
Novavax revises Takeda deal for Japan vaccine sales - Investing.com
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Taking a look at what insiders are doing to gauge the Takeda Pharmaceutical Co ADR (TAK)’s direction - knoxdaily.com
Takeda Pharmaceutical Co ADR [TAK] Insider Activity: An Update for Investors - knoxdaily.com
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):